UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of ~~February~~March 2026

001-43033

(Commission File Number)

PULSENMORE LTD.

(Exact name of Registrant as specified in its charter)

8 Omarim St.

Omer 8496500, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On ~~February~~March 918, 2026, Pulsenmore Ltd. ~~issued~~has aposted ~~press~~to ~~release~~its ~~entitled~~website ~~“Pulsenmore~~an ~~Builds~~updated Ucorporate presentation.S. ~~Momentum~~A ~~with~~copy ~~Another~~of the presentation is ~~Commercial~~furnished ~~Engagement~~with ~~Following~~this ~~FDA~~Report ~~Clearance”. A copy~~ of ~~the~~Foreign ~~press~~Private ~~release~~Issuer ison ~~attached~~Form ~~hereto~~6-K as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.		Description
99.1		~~Press~~Corporate ~~Release, dated February 9, 2026~~Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Pulsenmore Ltd.
Date: February 9, 2026	By:	/s/ Eran Hirsh
Date: March 18, 2026	By:	/s/ Eran Hirsh
		Eran Hirsh
		Chief Financial Officer

Filing Compare · Pulsenmore Ltd.